To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
Researchers from NeuroSpin and CNRGH (Jacob Institute) have studied, on a genome-wide scale, the potential associations of haplotypes (set of variants located side by side on a chromosome) with the opening value of imaged brain sulci, indicator of brain aging, from the UK Biobank neuroimaging-genetics cohort.
An international consortium of scientists, including an I2BC team, has just deciphered the functioning of FAP (Fatty Acid Photodecarboxylase), a key photoenzyme for the production of biofuels and other high value added molecules. This work, published in Science, was the object of a CEA press release.
Teams from IPMC and SIMoS (DMTS) defined the molecular determinants of the interaction between Mambalgin-1, an analgesic peptide isolated from black mamba venom, and its target, ASIC1 (Acid-Sensing Ion Channels), to model, using molecular dynamics, this complex. The resulting model provides clues to develop blockers of ASIC1, interesting targets for clinical pain relief applications.
A study by researchers from I2BC department shows in vitro the effect of mitotic phosphorylation of the BAF protein on its structure and its interactions with DNA and lamina and unveils consequences on genome organization and on mechanisms responsible for progeroid syndromes.
Researchers at CEA-Joliot (SPI unit in collaboration with SIMoS unit) have developed a monoclonal antibody directed against a common region of two proteins of the bacteria Shigella and Salmonella and capable of inducing cross-protection against infections caused by these bacteria.
By studying the structure-reactivity relationships of bio-inspired catalysts for CO2 reduction, researchers from I2BC (SB2SM) and ICMMO have shown that the effects of through-space electrostatic interactions surpass the through-bonds electronic effects. A further step towards obtaining a durable catalyst to reduce the atmospheric accumulation of CO2, responsible for global warming.
I2BC researchers, in collaboration with the European Institute of Chemistry and Biology (University of Bordeaux, CNRS), have developed a chimeric peptide/foldamer molecule that is resistant to proteolysis and inhibits ASF1, a potential target for anticancer treatment. The resolution of the structure of this chimera in interaction with its target, the first of its kind, reveals an unsuspected plasticity of the urea-based backbone that hugs the surface of ASF1.
The European Commission once more places its trust on Multiwave company and its partners, Aix-Marseille Université , CEA and Université Catholique de Louvain to revolutionize ultra-high field magnetic resonance imaging of the brain.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.